Table 1.
Baseline characteristics for patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors, stratified by treatment line and prior history of BCG
| First line ICI | Second or later line ICI | |||||
|---|---|---|---|---|---|---|
| History of BCG | No | Yes | P | No | Yes | P |
| Number of Patients | 287 | 78 | 205 | 75 | ||
| Age at ICI initiation, median (IQR) | 70 (67–82) | 69 (49–79) | 0.22 | 66 (59–80) | 77 (60–82) | <0.001 |
| Sex, N (%) | ||||||
| Male | 206 (72) | 63 (81) | 0.11 | 154 (75) | 66 (88) | 0.02 |
| Female | 81 (28) | 15 (20) | 51 (25) | 9 (12) | ||
| Smoking History, N (%) | ||||||
| Ever Smoker | 204 (72) | 49 (63) | 0.12 | 148 (72) | 51 (68) | 0.49 |
| Never Smoker | 80 (28) | 29 (37) | 57 (28) | 24 (32) | ||
| Race, N (%) | ||||||
| White race | 216 (75) | 61 (78) | 0.85 | 151 (74) | 57 (76) | 0.04 |
| Hispanic | 31 (11) | 6 (8) | 31 (15) | 4 (5) | ||
| African American | 16 (6) | 4 (5) | 12 (6) | 5 (7) | ||
| Asian | 8 (3) | 4 (5) | 8 (4) | 3 (4) | ||
| Histology, N (%) | ||||||
| Pure UC | 188 (66) | 56 (72) | 0.31 | 157 (77) | 57 (76) | 0.87 |
| Mixed UC | 98 (34) | 22 (28) | 47 (23) | 18 (24) | ||
| Non-UC | 1 (0) | 0 (0) | 1 (0) | 0 (0) | ||
| Prior platinum chemotherapy, N (%) | ||||||
| No | 148 (52) | 52 (67) | 0.018 | 14 (7) | 3 (4) | 0.38 |
| Yes | 139 (48) | 26 (33) | 191 (93) | 72 (96) | ||
| Albumin<3.5 g/dL at ICI initiation, N (%) | ||||||
| No | 96 (33) | 24 (31) | 0.48 | 63 (31) | 32 (43) | 0.07 |
| Yes | 171 (60) | 52 (67) | 131 (64) | 40 (53) | ||
| Hgb<10 g/dL at ICI initiation, N (%) | ||||||
| No | 212 (74) | 53 (68) | 0.29 | 144 (70) | 60 (80) | 0.14 |
| Yes | 68 (24) | 23 (30) | 55 (27) | 14 (19) | ||
| Liver Metastasis at ICI initiation, N (%) | ||||||
| No | 249 (87) | 63 (81) | 0.18 | 156 (76) | 57 (76) | 0.99 |
| Yes | 38 (13) | 15 (19) | 49 (24) | 18 (24) | ||
| ECOG Performance Status, N (%)a | ||||||
| 0 | 57 (20) | 18 (23) | 0.67 | 36 (18) | 18 (24) | 0.58 |
| 1 | 131 (46) | 32 (41) | 119 (58) | 40 (53) | ||
| 2 | 69 (24) | 18 (23) | 24 (12) | 11 (15) | ||
| 3 | 6 (2) | 3 (4) | 5 (2) | 1 (1) | ||
| 4 | 1 (0) | 1 (1) | 0 (0) | 0 (0) | ||
| Missing | 23 (8) | 6 (8) | 21 (10) | 5 (7) | ||
| ICI Received, N (%) | ||||||
| Atezolizumab | 113 (39) | 30 (39) | 0.37 | 110 (54) | 44 (60) | 0.18 |
| Avelumab | 1 (0) | 0 (0) | 1 (<1) | 0 (0) | ||
| Durvalumab | 7 (2) | 4 (5) | 6 (3) | 1 (1) | ||
| Nivolumab | 16 (6) | 1 (1) | 26 (13) | 4 (6) | ||
| Pembrolizumab | 147 (51) | 42 (54) | 60 (30) | 24 (33) | ||
| Risk Scoreb | ||||||
| 0 | 112 (39) | 24 (31) | 0.62 | 27 (13) | 11 (15) | 0.27 |
| 1 | 83 (29) | 22 (28) | 83 (41) | 38 (51) | ||
| 2 | 37 (13) | 12 (15) | 59 (29) | 19 (25) | ||
| 3c | 26 (9) | 7 (10) | 12 (6) | 1 (1) | ||
| Missing | 28 (10) | 12 (16) | 24 (11) | 6 (8) | ||
a
At time of ICI initiation
b
First-line: Internally developed risk score, Ali risk model (ECOG PS, liver mets, NLR, albumin) [13]; Second or later line: Bellmunt risk score (ECOG, liver mets, Hgb) [14]
c
First-line risk score includes four factors thus score of 3 is ≥3